GovBidAlerts
OpenSolicitationFederal

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Department of Defense · Defense Health Agency (dha)

Due Closes in 19 daysRef. HT9402-27-Q-9101

At a glance

What

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents.

Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412)

Who can bid
Any business — no set-aside listed
Where
San Antonio, TX
Key dates
  • Posted: Nov 12, 2026
  • Deadline: Mon, Dec 7, 2026 · 12:00 PM CST (closes in 19 days)
How to respond

Stephanie Erpelding · stephanie.j.erpelding.civ@health.mil

Submit per the instructions on SAM.gov ↗

Documents
None attached here — check SAM.gov

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).
Read more ↓
Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
All notice detailsShow ↓
Solicitation number
HT9402-27-Q-9101
Notice type
Solicitation
Product/service code (PSC)
6505
Department
Department of Defense
Sub-agency
Defense Health Agency (dha)
Contracting office
DEFENSE HEALTH AGENCY
Office location
AURORA, CO, 80011
Place of performance
San Antonio, TX, 78230
Archive date
Mar 12, 2027
Archive type
autocustom
Organization type
OFFICE
Full agency path
DEPT OF DEFENSE.DEFENSE HEALTH AGENCY (DHA).DEFENSE HEALTH AGENCY
SAM.gov notice ID
4379b35024844e9e8afaa128b80b3809

Contacts